Triamcinolone
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H318901

CAS#: 124-94-7 (free)

Description: Triamcinolone is used to treat a number of different medical conditions, such as eczema, psoriasis, arthritis, allergies, ulcerative colitis, lupus, sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammation, Urushiol-induced contact dermatitis, aphthous ulcers (usually as triamcinolone acetonide), visualization during vitrectomy and the prevention of asthma attacks. It will not treat an asthma attack once it has already begun. It has also been used off-label for macular degeneration.


Chemical Structure

img
Triamcinolone
CAS# 124-94-7 (free)

Theoretical Analysis

Hodoodo Cat#: H318901
Name: Triamcinolone
CAS#: 124-94-7 (free)
Chemical Formula: C21H27FO6
Exact Mass: 394.18
Molecular Weight: 394.439
Elemental Analysis: C, 63.95; H, 6.90; F, 4.82; O, 24.34

Price and Availability

Size Price Availability Quantity
100mg USD 150 2 Weeks
200mg USD 250 2 Weeks
500mg USD 450 2 Weeks
1g USD 650 2 Weeks
2g USD 1050 2 Weeks
5g USD 1950 2 Weeks
Bulk inquiry

Related CAS #: 124-94-7 (free)   76-25-5 (acetonide)   67-78-7 (diacetate)   5611-51-8 (hexacetonide)    

Synonym: BRN-2341955; BRN2341955; BRN 2341955; Triamcinolone; Adcortyl; Aristocort

IUPAC/Chemical Name: (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one

InChi Key: GFNANZIMVAIWHM-OBYCQNJPSA-N

InChi Code: InChI=1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1

SMILES Code: C[C@@]12[C@](C(CO)=O)(O)[C@H](O)C[C@@]1([H])[C@]3([H])CCC4=CC(C=C[C@]4(C)[C@@]3(F)[C@@H](O)C2)=O

Appearance: White to off-white crystalline powder.

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 394.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Jin E, Luo L, Bai Y, Zhao M. Comparative effectiveness of intravitreal bevacizumab with or without triamcinolone acetonide for treatment of diabetic macular edema. Ann Pharmacother. 2015 Apr;49(4):387-97. doi: 10.1177/1060028014568006. Epub 2015 Jan 26. Review. PubMed PMID: 25622852.

2: Nanno M, Sawaizumi T, Kodera N, Tomori Y, Takai S. Flexor pollicis longus rupture in a trigger thumb after intrasheath triamcinolone injections: a case report with literature review. J Nippon Med Sch. 2014;81(4):269-75. Review. PubMed PMID: 25186581.

3: Sadarangani S, Berg ML, Mauck W, Rizza S. Iatrogenic cushing syndrome secondary to ritonavir-epidural triamcinolone interaction: an illustrative case and review. Interdiscip Perspect Infect Dis. 2014;2014:849432. doi: 10.1155/2014/849432. Epub 2014 May 7. Review. PubMed PMID: 24895495; PubMed Central PMCID: PMC4033556.

4: Scherer J, Rainsford KD, Kean CA, Kean WF. Pharmacology of intra-articular triamcinolone. Inflammopharmacology. 2014 Aug;22(4):201-17. doi: 10.1007/s10787-014-0205-0. Epub 2014 May 14. Review. PubMed PMID: 24824076.

5: Ciulla TA, Harris A, McIntyre N, Jonescu-Cuypers C. Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant. Expert Opin Pharmacother. 2014 May;15(7):953-9. doi: 10.1517/14656566.2014.896899. Epub 2014 Mar 24. Review. PubMed PMID: 24661081.

6: Kassim JM, Shipman AR, Szczecinska W, Siah TW, Lam M, Chalmers J, Macbeth AE. How effective is intralesional injection of triamcinolone acetonide compared with topical treatments in inducing and maintaining hair growth in patients with alopecia areata? A Critically Appraised Topic. Br J Dermatol. 2014 Apr;170(4):766-71. doi: 10.1111/bjd.12863. Review. PubMed PMID: 24484438.

7: Jin ZY, Zhu D, Tao Y, Wong IY, Jonas JB. Meta-analysis of the effect of intravitreal bevacizumab versus intravitreal triamcinolone acetonide in central retinal vein occlusion. J Ocul Pharmacol Ther. 2013 Nov;29(9):826-31. doi: 10.1089/jop.2013.0061. Epub 2013 Aug 24. Review. PubMed PMID: 23971622.

8: Song Y, Schroeder JR, Bush LM. Iatrogenic Cushing syndrome and secondary adrenal insufficiency related to concomitant triamcinolone and ritonavir administration: a case report and review. J Int Assoc Provid AIDS Care. 2014 Nov-Dec;13(6):511-4. Review. PubMed PMID: 23778239.

9: Athanasiadis Y, Tsatsos M, Sharma A, Hossain P. Subconjunctival triamcinolone acetonide in the management of ocular inflammatory disease. J Ocul Pharmacol Ther. 2013 Jul-Aug;29(6):516-22. doi: 10.1089/jop.2012.0208. Epub 2013 Mar 13. Review. PubMed PMID: 23485045.

10: Fredman R, Tenenhaus M. Cushing's syndrome after intralesional triamcinolone acetonide: a systematic review of the literature and multinational survey. Burns. 2013 Jun;39(4):549-57. doi: 10.1016/j.burns.2012.09.020. Epub 2012 Oct 23. Review. PubMed PMID: 23092701.

11: Haque MN, Basu S, Padhi TR, Kesarwani S. Acute idiopathic frosted branch angiitis in an 11-month-old infant treated with intravitreal triamcinolone acetonide. J AAPOS. 2012 Oct;16(5):487-8. doi: 10.1016/j.jaapos.2012.06.002. Review. PubMed PMID: 23084392.

12: Qi HP, Bi S, Wei SQ, Cui H, Zhao JB. Intravitreal versus subtenon triamcinolone acetonide injection for diabetic macular edema: a systematic review and meta-analysis. Curr Eye Res. 2012 Dec;37(12):1136-47. doi: 10.3109/02713683.2012.705412. Epub 2012 Jul 13. Review. PubMed PMID: 22793880.

13: McGuire E. Sudden loss of milk supply following high-dose triamcinolone (Kenacort) injection. Breastfeed Rev. 2012 Mar;20(1):32-4. Review. PubMed PMID: 22724311.

14: Abu-Mugheisib M, Benecke R, Zettl UK. Management of spasticity in progressive multiple sclerosis: efficacy of repeated intrathecal triamcinolone acetonide administration. Curr Pharm Des. 2012;18(29):4564-9. Review. PubMed PMID: 22612755.

15: Han JM, Ahn J, Park KH, Woo SJ. Presumed necrotizing viral retinitis after intravitreal triamcinolone injection: case report. Korean J Ophthalmol. 2011 Dec;25(6):451-4. doi: 10.3341/kjo.2011.25.6.451. Epub 2011 Nov 22. Review. PubMed PMID: 22131785; PubMed Central PMCID: PMC3223715.

16: Veritti D, Di Giulio A, Sarao V, Lanzetta P. Drug safety evaluation of intravitreal triamcinolone acetonide. Expert Opin Drug Saf. 2012 Mar;11(2):331-40. doi: 10.1517/14740338.2012.635141. Epub 2011 Nov 9. Review. PubMed PMID: 22066820.

17: Yilmaz T, Cordero-Coma M, Federici TJ. Pharmacokinetics of triamcinolone acetonide for the treatment of macular edema. Expert Opin Drug Metab Toxicol. 2011 Oct;7(10):1327-35. doi: 10.1517/17425255.2011.606215. Epub 2011 Jul 27. Review. PubMed PMID: 21790508.

18: Yilmaz T, Cordero-Coma M, Lavaque AJ, Gallagher MJ, Padula WV. Triamcinolone and intraocular sustained-release delivery systems in diabetic retinopathy. Curr Pharm Biotechnol. 2011 Mar 1;12(3):337-46. Review. PubMed PMID: 20939800.

19: Becerra EM, Morescalchi F, Gandolfo F, Danzi P, Nascimbeni G, Arcidiacono B, Semeraro F. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration. Curr Drug Targets. 2011 Feb;12(2):149-72. Review. PubMed PMID: 20887246.

20: Frasiolas JA, Cahoon WD. Intrapericardial triamcinolone administration for autoreactive pericarditis. Ann Pharmacother. 2010 Oct;44(10):1641-6. doi: 10.1345/aph.1P294. Epub 2010 Aug 24. Review. PubMed PMID: 20736423.